First-Half 2024 Results

Marcy l’Etoile (France), September 5^th, 2024 – The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on September 4^th under the chairmanship of Alexandre Mérieux and approved the consolidated financial statements for the six months ended June 30, 2024:

• +9.9% organic sales growth in H1 at €1,902m driven by the strong performance of the GO•28 strategic plan’s four growth engines, together with BIOFIRE^®* respiratory panels:

• BIOFIRE^®*non-respiratory panels up +19%, a strong and balanced performance with each region and each panel growing at least double digit
• Microbiology: +8.7%, with reagents growing +13% driven by volumes and price increases
• SPOTFIRE^®*: €33m of sales (€13m in Q2) in line with the €80m 2024 sales guidance, offering now the most comprehensive suite of respiratory assays in the segment.
• Industrial Applications: +11% on reagents (+7% total), with a strong bounce back of the food segment and a positive dynamic on prices
• BIOFIRE^® respiratory panels up +14%, demonstrating the competitiveness of the solution and the strong leverage of the existing installed base.

• €937 million of sales in Q2 2024, up +10.1% like-for-like

• GO•28 deployment kicked-off in Q2 on all 4 dimensions

• Contributive operating income before non-recurring items (CEBIT) reached €306 million for the first half of the year, representing a +155bps CEBIT margin improvement at constant exchange rate vs H1 2023 and a steady +20% like-for-like evolution versus H1 2023, perfectly on track to increase the 2024 CEBIT by at least +10% as per the GO•28 commitment. The reported evolution stands at +5%, negatively impacted by a -€44m currency effect.

• Net income (group share) of €215m, increased by +33% versus the H1 2023 performance which was negatively impacted by the Hybiome (Chinese immunoassays entity) goodwill impairment.

• 2024 full year guidance revised upward: sales expected to grow organically by +8% to +10% (6% to 8% initially) and CEBIT to grow by +12% to +17% organically (at least +10% initially). The full year exchange rates impact is expected to be negative in the range of -€70m (-€50m initially).

* In this document, BIOFIRE® refers to BIOFIRE® FILMARRAY® TORCH system and panels and SPOTFIRE® refers to BIOFIRE® SPOTFIRE® system and panels